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ABSTRACT
Skin involvement in systemic lupus erythematosus (SLE) occurs in more than 75% of patients with this condition. Vesicles 
and blisters in lupus erythematosus (LE) may be present in SLE secondary to interface vacuolar changes in the epidermis, 
in discoid LE also secondary to vacuolar epidermal changes, and in bullous LE secondary to antibodies anti-collagen VII 
deposits with neutrophilic aggregates. In addition, blisters can occur due to the association of SLE with other autoimmune 
blistering diseases (e.g. bullous pemphigoid). BSLE is a rare blistering disease that mainly occurs in females (30–40 years old), 
and less frequently in children and adolescents. The most common presentation is rapid and widespread development of 
tense vesicles and bullae over erythematous macules or plaques. Preferential sites are: superior trunk, proximal superior 
limbs, and face (lips) with symmetrical distribution. Mucosal involvement is common on perioral, pharyngeal, laryngeal, 
and genital areas. The involvement of sun-exposed areas is not mandatory. The lesions usually progress with no scarring, 
but hypo or hyperchromia may be present. We report an 18-year-old female patient with blistering lesions at admission, 
who was diagnosed with BSLE. She was initially treated with systemic prednisone and hydroxychloroquine. Her condition 
evolved with relapsing lesions, which required the introduction of Dapsone. The authors emphasize the relevance of 
recognizing BSLE—a rare presentation of SLE—which may evolve with marked clinical presentation. 
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INTRODUCTION
Skin involvement in systemic lupus erythematosus 
(SLE) occurs in more than 75% of patients with this 
condition. Vesicles and blisters in SLE may be detected 
in three different conditions: (1) due to an interface 
vacuolar dermatitis; (2) due to the association of 
SLE with other autoimmune blistering diseases (e.g. 
bullous pemphigoid); and (3) due to an autoimmune 
blistering disease related to antibodies anti-collagen 
VII. This last condition refers to bullous systemic lupus 
erythematous (BSLE).
BSLE is a rare blistering disease that mainly 
occurs in females (3–40 years old), and less frequently 
in children and adolescents.1-2 The involvement of 
sun-exposed areas is not mandatory, and is marked 
by the rapid and widespread development of tense 
vesicles and bullae over erythematous macules or 
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plaques. Preferential sites are: superior trunk, proximal 
superior limbs, and face (lips)3 with symmetrical 
distribution. Mucosal involvement is common on 
perioral, pharyngeal, laryngeal, and genital areas. 
The lesions usually progress with no scarring, but hypo 
or hyperchromia may be present.
CASE REPORT
An 18-year-old female was hospitalized presenting 
slightly painful and pruritic vesicles and bullae on the 
face, oral mucosa, abdomen, thighs, and dorsum 
over the last 2 weeks. She also reported weight loss, 
migratory polyarthralgia with morning stiffness longer 
than 30 minutes, myalgia, fatigue, fever, alopecia, and 
malar rash associated with photosensitivity over the 
last 2 months. She was taking medroxyprogesterone 
acetate every 3 months as a contraceptive method. Her 
past medical history included a pregnancy at the age 
of 17, with low titers in the Venereal Disease Research 
Laboratory test, and a negative treponemal test.
The admission clinical examination revealed a 
prostrated and pale patient, with normal vital signs. 
Skin findings showed the presence of a malar rash, 
and multiple tense vesicles and bullae varying from 
1 mm to 6 cm, over erythematous macules and plaques 
(Figure 1). These lesions were present on the face, 
including eyelids, arms, abdomen, dorsum, and thighs. 
Involvement of the vermilion border of the lips and 
oral mucosa was present. No lymphadenopathy and 
signs of arthritis were detected; the remaining physical 
examination revealed no alterations.
BSLE was considered as the first hypothesis, 
followed by the differential diagnosis of other 
conditions, such as: epidermolysis bullosa acquisita, 
bullous pemphigoid, dermatitis herpetiformis, linear 
immunoglobulin (Ig)A bullous dermatosis, and drug 
eruption.
Genera l  l abo ra to r y  eva lua t ion  showed 
a complete blood cell count with pancytopenia 
hemoglobin levels of 11.0 g/dL (reference range [RR]: 
12.3–15.3 g/dL), leukocytes of 2880 per mm3 (RR: 
4.4–11.3 × 103/mm3) and platelet count of 105,000 
per mm3 (RR: 150–400 × 103 /mm3). The direct Coombs 
assay was positive, but lactate dehydrogenase and 
bilirubin were at normal levels. Urinalysis revealed the 
presence of proteinuria, hematuria, and leukocyturia, 
with no casts. The spot urine protein/creatinine ratio 
was 856 mg/g (RR: < 300 mg/g). Renal function was 
preserved (creatinine of 0.63 mg/dL [RR: 0.4–1.3 mg/dL] 
and urea of 15 mg/dL [RR: 5–25 mg/dL]). Complement 
was at low levels, C3 < 21 mg/dL (RR: 67–149 mg/
dL) and C4 = 7 mg/dL (RR: 10–38mg/dL); anti-nuclear 
antibody was positive (1/640) with a homogeneous 
nuclear pattern, anti-double-stranded DNA and anti-
histone were positive.
Skin histopathology revealed subepidermal 
cleavage with a neutrophilic inflammatory infiltrate 
(Figure 2). Direct immunofluorescence (DIF) showed 
positivity for IgG at the basement membrane zone 
(BMZ) in a linear pattern (Figure 3A). Salt-split skin 
indirect immunofluorescence showed the presence of 
IgG deposits at the dermal side of cleavage (negative 
for IgA and IgM) (Figure 3B). ELISA was positive for 
antibodies against type VII collagen.
The clinical and laboratory findings confirmed the 
diagnosis of BSLE.
The patient was treated with oral prednisone 
1 mg/kg/d along with hydroxychloroquine 400 mg/d 
5 days per week. Skin lesions and other SLE symptoms 
markedly improved after 1 week of treatment and 
the patient was discharged. However, the skin lesions 
on the vermilion border of the lips, eyelids, forearms, 
dorsum, and thighs relapsed soon after, despite 
adherence to treatment. Hospitalization was necessary 
due to the extent of skin involvement and systemic 
symptoms. Dapsone 200 mg/d was added to the 
Figure 1. BSLE. Arciform and linear tense bullae of 
varying sizes over erythematous macules and plaques 
on abdomen, thighs (A) and dorsum (B). BSLE = bullous 
systemic lupus erythematous.
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Figure 2. BSLE. Skin histopathology. A – Subepidermal cleavage with neutrophils. The inflammatory cells are disposed 
along the papillary dermis; B – Subepidermal cleavage partially filled with neutrophils; C – Subepidermal blister 
with neutrophils and inflammatory cells at the periphery of the bulla; D – Neutrophils are present in the superficial 
dermis. Note the thickening of the basement membrane. (H&E, A:100X; B, C, and D: 400X). BSLE = bullous systemic 
lupus erythematous.
Figure 3. A – Direct immunofluorescence shows homogenous IgG deposit at the basement membrane zone (400X); 
B – Indirect immunofluorescence (salt-split skin), human foreskin substrate: IgG deposits at the dermal side of the 
split (400X).
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therapeutic regimen, with subsequent improvement 
of the clinical features. Hydroxychloroquine was 
withdrawn due to hemolysis.
DISCUSSION
BSLE is a rare autoimmune blistering disorder 
that usually presents as tense bullae and/or vesicles 
in patients with a previously known or concurrent 
diagnosis of SLE. Due to the rarity of the disease, 
epidemiologic data are limited. A French study4 showed 
an incidence of bullous skin disorders (excluding 
bullous pemphigoid) of 3.4 cases per million per 
year. The occurrence of BSLE among children and 
adolescents with SLE is around 1%.2 Data on BSLE are 
scarce; therefore, the knowledge about the disease is 
mostly based on case reports or case series.
BSLE patients usually present with clinical features 
of SLE. The blisters predominantly occur on the face, 
neck, upper extremities, oral mucosa, and vermilion 
border. Development of bullae is triggered by sun 
exposure. Bullous lesions are tense and heal with no 
scarring.5-13 Mucosal involvement features include 
either blisters or painless ulcers. Esophagitis dissecans 
was reported.14 Differential diagnoses usually include 
other subepidermal bullous diseases such as bullous 
pemphigoid (BP), epidermolysis bullosa acquisita 
(EBA), linear IgA bullous dermatosis, and dermatitis 
herpetiformis (DH).15
The histopathology of BSLE usually shows a 
subepidermal bullae with neutrophil-predominant 
inflammatory infiltrate below the bullae formation. 
The presence of micro abscesses in the dermal papillae is 
also frequent, which makes the histopathology features 
of BSLE very similar to DH.16 In BSLE, neutrophils tend 
to be in a dispersed arrangement (Figure 2C) and may 
extend into the papillary dermal collagen (Figure 2D). 
Deposits of mucin are often seen in the deep dermis.17 
In counterpart, the neutrophilic infiltrate in DH is focal 
and localized at the papillary dermis.
The immunopathologic findings in BSLE include: 
direct immunofluorescence with linear IgG deposits 
at BMZ, and occasional granular IgA, IgM, and C3 
deposits.17 Salt-split skin indirect immunofluorescence 
reveals IgG deposition at the dermal side of cleavage, 
and is a helpful tool for BSLE.13 The presence of 
autoantibodies against type VII collagen may be 
detected in patients with BSLE.18,19
Camisa and Sharma20 were the first authors to 
establish diagnostic criteria for BSLE. In 1988, with the 
use of immunofluorescence, these diagnostic criteria 
were reviewed and are shown in Table 1.21,22
The current therapeutic regimens for BSLE 
are based on the pathogenesis of the disease, 
case-reports, and case-series. Dapsone is used as 
first-line therapy6,11,23-25 along with glucocorticoids 
and immunosuppressants. Other therapeutic options 
include mycophenolate mofetil5,7,13,26 methotrexate,27 
rituximab,28 hydroxychloroquine and intravenous 
immunoglobulin.8
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